Free Access
Med Sci (Paris)
Volume 21, Number 6-7, Juin–Juillet 2005
Page(s) 669 - 670
Section Derniére Heure
Published online 15 June 2005
  1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) : classification of myeloid neoplasms. Blood 2002; 100 : 2292–302. [Google Scholar]
  2. Wong S, Witte ON. The BCR-ABL story : bench to bedside and back. Annu Rev Immunol 2004; 22 : 247–306. [Google Scholar]
  3. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002; 16 : 1207–12. [Google Scholar]
  4. Gotlib J, Cools J, Malone JM, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia implications for diagnosis, classification and management. Blood 2004; 103 : 2879–91. [Google Scholar]
  5. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004; 104 : 1931–9. [Google Scholar]
  6. Wadleigh M, De Angelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia : tyrosine kinase inhibitors in others malignancies. Blood 2005; 105 : 22–30. [Google Scholar]
  7. Pahl HL. Towards a molecular understanding of polycythemia rubra vera. Eur J Biochem 2000; 267: 3395–401. [Google Scholar]
  8. Spivak JL. Polycythemia vera : myths, mechanisms, and management. Blood 2002; 100 : 4272–90. [Google Scholar]
  9. Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004; 32 : 179–87. [Google Scholar]
  10. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434 : 1144–8. [Google Scholar]
  11. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30 : 229–36. [Google Scholar]
  12. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365 : 1054–61. [Google Scholar]
  13. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352 : 1779–90. [Google Scholar]
  14. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7 : 387–97. [Google Scholar]
  15. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in Polycythemia vera. J Biol Chem 2005 online. [Google Scholar]
  16. Goldman JM. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 2005; 352 : 1744–6. [Google Scholar]
  17. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders : it all makes sense. Blood 2005; 105 : 4187–90. [Google Scholar]
  18. Shannon K, Van Etten RA. JAKing up hematopoietic proliferation. Cancer Cell 2005; 7 : 291–3. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.